Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-03-22
2011-03-22
Gussow, Anne M. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S326000, C530S387100, C530S389100
Reexamination Certificate
active
07910332
ABSTRACT:
The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses.
REFERENCES:
patent: 6849259 (2005-02-01), Haurum et al.
patent: 7262028 (2007-08-01), Van Berkel et al.
patent: 2005/0170398 (2005-08-01), Van Berkel et al.
patent: 2006/0275766 (2006-12-01), Haurum et al.
patent: 2007/0141048 (2007-06-01), Oleksiewicz et al.
patent: 1 293 564 (2003-03-01), None
patent: 1 484 402 (2004-12-01), None
patent: WO 91/16074 (1991-10-01), None
patent: WO 98/37186 (1998-08-01), None
patent: WO 2004/029284 (2004-04-01), None
patent: WO 2004/061104 (2004-07-01), None
patent: WO 2005/042774 (2005-05-01), None
patent: WO 2006/007850 (2006-01-01), None
patent: WO 2006/007853 (2006-01-01), None
patent: WO 2007/065433 (2007-06-01), None
patent: WO 2007/101441 (2007-09-01), None
Sautter and Enenkel. Selection of high-producing CHO cells using NPT selection marker with reduced enzyme activity. Biotechnology and Bioengineering, 2005. vol. 89, pp. 530-538.
Boder, E.T. and Wittrup, K.D., “Yeast surface display for screening combinatorial polypeptides libraries,”Nat. Biotechnol. 15:553-557, Nature Publishing Group (1997).
Bregenholt, S., et al., “Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections,”Curr. Pharm. Des. 12:2007-2015, Bentham Science Publishers (Jan. 2006).
Brezinsky, S.C.G., et al., “A simple method for enriching populations of transfected CHO cells for cell of higher specific productivity,”J. Immunol. Meth. 277:141-155, Elsevier Science (2003).
Canfield, S.M. and Morrison, S.L., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region,”J. Exp. Med. 173:1483-1491, Rockefeller University Press (1991).
Cull, M.G., et al., “Screening for receptor ligands using large libraries of peptides linked to the C terminus of thelacrepressor,”Proc. Natl. Acad. Sci. U.S.A. 89:1865-1869, National Academy of Science (1992).
Czerinsky, C.C., et al., “A Solid-Phase Enzyme-Linked Immunospot (ELISPOT) Assay for Enumeration of Specific Antibody-Secreting Cells,”J. Immunol. Meth. 65:109-121, Elsevier Science (1983).
Dreher, M.L., et al., “Colony assays for antibody fragments expressed in bacteria,”J. Immunol. Methods139:197-205, Elsevier Science (1991).
Fuchs, P., et al., “Targeting Recombinant Antibodies to the Surface ofEscherichia Coli: Fusion to a Peptidoglycan Associated Lipoprotein,”Biotechnology 9:1369-1372, Nature Publishing Group (1991).
Grabherr, R. and Ernst, W., “The Baculovirus Expression System as a Tool for Generating Diversity by Viral Surface Display,”Comb. Chem. High Throughput Screen. 4:185-192, Bentham Science Publishers (2001).
Haurum, J. and Bregenholt, S., “Recombinant polyclonal antibodies: Therapeutic antibody technologies come full circle,”IDrugs 8:404-409, Thomson Scientific (May 2005).
Haurum, J.S., “Recombinant polyclonal antibodies: the next generation of antibody therapeutics?,”Drug Discov. Today 11:655-660, Elsevier Science (Jul. 2006).
Huang, Y., et al., “An efficient and targeted gene integration system for high-level antibody expression,”J. Immunol. Methods 322:28-39, Elsevier Science (Apr. 2007).
Kang, A.S., et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,”Proc. Natl. Acad. Sci. 88:4363-4366, National Academy of Science (1991).
Kito, M., et aL, “Construction of engineered CHO strains for high-level production of recombinant proteins,”Appl. Microbiol. Biotechnol. 60:442-448, Springer-Verlag (2002).
Kumpel, B.M., et al., “Section 1C: Assessment of the functional activities and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies,”Transfus. Clin. Biol. 9:45-53, Elsevier Science (2002).
Logtenberg, T., “Antibody cocktails: next-generation biopharmaceuticals with improved potency,”Trends Biotechnol. 25:390-394, Elsevier Science (Sep. 2007).
Meijer, P.-R., et al., “Isolation of Human Antibody Repertoires with Preservation of the Natural Heavy and Light Chain Pairing,”J. Mol. Biol. 358:764-772, Elsevier Science (May 2006).
Poulsen, T.R., et al., “Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses against Tetanus Toxoid,”J. Immunol. 179:3841-3850, The American Association of Immunologists (Sep. 2007).
Roberts, R.W. and Szostak, J.W., “RNA-peptide fusions for the in vitro selection of peptides and proteins,”Proc. Natl. Acad. Sci. 94:12297-12302, National Academy of Sciences (1997).
Schaffitzel, C., et al., “Ribosome display: an in vitro method for selection and evolution of antibodies from libraries,”J. Immunol. Meth. 231:119-135, Elsevier Science (1999).
Sharon, J., et al., “Recombinant Polyclonal Antibodies for Cancer Therapy,”J. Cell. Biochem. 96:305-313, Wiley-Liss (2005).
Söderlind, E., et al., “Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries,”Nat. Biotechnol. 18:852-856, Nature Publishing Group (2000).
Stirnadel, H.A., et al., “Genetic analysis of IgG subclass responses against RESA and MSP2 of Plasmodium falciparum in adults in Papua New Guinea,”Epidemiol. Infect. 124:153-162, Cambridge University Press (2000).
Tolstrup, A.B., et al., “Development of recombinant human polyclonal antibodies for the treatment of complex human diseases,”Expert Opin. Biol. Ther. 6:905-912, Ashley Publications (Sep. 2006).
Wiberg, F.C., et al., “Production of Target-Specific Recombinant Human Polyclonal Antibodies in Mammalian Cells,”Biotechnol. Bioeng. 94:396-405, Wiley (Jun. 2006).
Muller Christian
Nielsen Lars Soegaard
Tolstrup Anne Bondgaard
Weilguny Dietmar
Wiberg Finn C.
Gussow Anne M.
Sterne Kessler Goldstein & Fox P.L.L.C.
Symphogen A/S
LandOfFree
Method for manufacturing a recombinant polyclonal protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for manufacturing a recombinant polyclonal protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for manufacturing a recombinant polyclonal protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712783